Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Thymosin beta4 derivative and its use

A derivative, thymosin technology, applied in the field of protein drug derivatives, can solve the problem of heart disease therapy changing the way medical staff deal with heart disease

Active Publication Date: 2009-05-06
BEIJING NORTHLAND BIOTECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The findings, made in rat experiments, could eventually lead to new treatments for heart disease and could change the way healthcare professionals manage heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Thymosin beta4 derivative and its use
  • Thymosin beta4 derivative and its use
  • Thymosin beta4 derivative and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0014] The following examples are only illustrations of the present invention, and do not impose any limitation on the present invention.

[0015] 1) Obtaining thymosin β4 derivatives

[0016] First, the whole gene sequence of thymosin β4 precursor protein was amplified by whole gene synthesis:

[0017] GGA TCC GAC AAA CCC GAT ATG GCT GAG ATC GAG AAA TTC GAT AAG TCG AAA

[0018] CTGAAG AAG ACA GAG ACG CAA GAG AAA AAT CCA CTG CCT TCC AAA GAA ACG

[0019] ATT GAA CAG GAG AAG CAA GCA GGC GAA TCG TAA GTC GAC

[0020] Using the GST gene as a template, a product of about 500 bp was amplified by PCR. After sequencing plasmid cloning and gene sequencing, the designed sequence was obtained for future use.

[0021] The target fragments were digested by BamH I, EcoR I, and XhoI to recover small fragments respectively, and the plasmid PGM was digested by XhoI and EcoRI to recover large fragments, and the three target gene fragments were ligated in the T4 ligase system at 18°C. The rec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to one section of thymosin beta 4 derivatives with high bioactivity which can be used to repair cornea, skin, and heart injury.

Description

1. Technical field [0001] The present invention belongs to the field of production of protein drug derivatives. By modifying the natural protein thymosin β4 (Tβ4), a derivative of Tβ4, Gly-Tβ4, was obtained. Experiments have proved that the derivative plays a very important role in the repair process of damaged tissues, and is expected to be developed as a new drug for the benefit of human beings. 2. Background technology [0002] The immune system is the body's defense system. The main cells involved in the immune response are T lymphocytes, B lymphocytes and macrophages. The thymus is the central immune organ for the development and differentiation of T lymphocytes. Thymus factors (or hormones) secreted by the thymus are a series of essential substances required for the development and differentiation of T lymphocytes, among which thymosin β4 (Tβ4) is a major thymus factor whose structure and function have been clarified. Thymosin-beta 4 enhanced embryonic and postnata...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/575A61K38/22A61P27/02A61P9/10A61P17/02
Inventor 聂李亚马素永许松山文美玉
Owner BEIJING NORTHLAND BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com